YOLFTbeta
30

Shanghai Universal Biotech Co.Ltd.

301166 · SHE · Healthcare / Biotechnology

28.68CNY-1.36 (-4.53%)

Price History

Full chart

Market Stats

Previous Close30.04
Open29.58
Day Range28.57 – 30.26
52-Week Range23.89 – 35.65
Volume2.29M
Market Cap3.05B
P/E (TTM)0.00
Forward P/E0.00
EPS-0.25
Dividend Yield1.70%
Beta1.06
50-Day Avg28.72
200-Day Avg29.99

About

Shanghai Universal Biotech Co.,Ltd. distributes and supplies antibodies and protein products. The company offers antibodies, recombinant proteins, detection kits, antigens, and other products, as well as immunology reagents, molecular biology reagents, cell biology reagents and biochemical reagents, as well as reagent kits. It also provides technical services, technology promotion, technology information exchange, scientific and technology training, technology consulting, technology incubation and other services, as well as experimental services and software solutions. The company also sells products online. It serves colleges and universities, research institutes, hospitals, and biomedical companies. The company was founded in 2004 and is based in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Zhaowu Leng
  • Employees832
  • HeadquartersBuilding 16, Shanghai, China, 201314, China
  • Websitehttps://www.univ-bio.com

Leadership

  • Mr. Zhaowu LengChairman & GM · b. 1970
  • Ms. Min TangCFO, Deputy GM & Director · b. 1980
  • Ms. Xiaoping XuDeputy GM & Director · b. 1970
  • Mr. Yin ZhouDeputy GM & Director · b. 1981
  • Ms. Yanfang QiBoard Secretary & Deputy GM · b. 1980
  • Ms. Waying ChenDeputy General Manager · b. 1984
  • Ms. Bing HuDeputy General Manager · b. 1983
  • Ms. Wei LiaoDeputy General Manager · b. 1984

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue786.93M849.08M1.11B1.20B1.23B1.12B1.08B
Growth (%)-+7.90%+30.69%+7.70%+2.57%-8.82%-3.05%
Cost of Revenue611.69M655.74M852.31M928.47M985.36M915.91M880.13M
Gross Profit175.24M193.34M257.36M266.66M240.47M201.85M203.57M
Gross Margin22.27%22.77%23.19%22.31%19.62%18.06%18.79%
Operating Expense95.30M97.19M119.27M161.63M225.12M227.37M245.52M
Operating Income79.94M96.15M138.09M105.03M15.35M-25.53M-41.95M
Operating Margin10.16%11.32%12.44%8.79%1.25%-2.28%-3.87%
EBITDA97.70M109.65M144.42M141.49M56.42M24.26M-7.44M
EBITDA Margin12.41%12.91%13.01%11.84%4.60%2.17%-0.69%
Net Income57.94M76.49M108.73M106.60M40.32M10.15M-22.95M
Net Income Margin7.36%9.01%9.80%8.92%3.29%0.91%-2.12%
R&D8.63M8.73M16.77M34.37M58.61M62.77M67.01M
R&D as % of Total Revenue1.10%1.03%1.51%2.88%4.78%5.62%6.18%
Interest Expense6.19M388.38K112.56K1.29M2.06M1.04M904.42K
Interest Expense % of Total Revenue0.79%0.05%0.01%0.11%0.17%0.09%0.08%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets504.82M591.27M2.31B2.48B2.39B2.31B2.30B
Total Liabilities175.45M186.47M224.80M326.77M274.23M241.52M296.56M
Total Equity329.37M404.79M2.09B2.16B2.12B2.07B2.01B
Cash152.54M250.63M1.87B732.14M414.53M840.16M545.52M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow9.63M92.23M59.02M-143.30M-22.69M75.97M52.43M
Capital Expenditure5.47M4.95M14.31M61.50M63.18M71.20M96.05M
Free Cash Flow4.16M87.28M44.72M-204.80M-85.87M4.77M-43.62M
Dividends Paid20.73M382.12K20.20M44.26M78.84M40.72M19.98M
FCF to OCF43.23%94.63%75.76%142.91%378.42%6.28%-83.20%
Dividend Paid to FCF497.86%0.44%45.17%-21.61%-91.81%853.76%-45.81%

Earnings

Report DateDec 31, 2021Apr 26, 2022Aug 29, 2022Oct 26, 2022Dec 31, 2022Apr 26, 2023Aug 28, 2023Oct 27, 2023Dec 31, 2023Apr 22, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Apr 28, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate-------------------
EPS Actual0.340.250.220.440.320.320.190.070.000.060.11-0.01-0.05-0.07-0.08-0.02-0.09-0.10-0.04
Surprise-------------------
Timing-Pre-marketAfter-hoursPre-market-Pre-marketPre-marketAfter-hours-Pre-market---Pre-market-----

Key Statistics & Ratios

Market Cap3.05B
Enterprise Value1.85B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.65
Price / Book1.47
EPS-0.25
Book Value23.15
Revenue (TTM)1.15B
Gross Profit (TTM)226.83M
EBITDA-48.27M
Profit Margin-1.86%
Operating Margin-4.13%
Return on Equity-1.08%
Return on Assets-1.82%
Shares Outstanding86.17M
Shares Float39.55M
Beta1.06
Dividend Yield1.70%
Dividend Rate0.60
Payout Ratio391.67%

Dividends

20261×
0.60Jun 1, 2026
20251×
0.23May 22, 2025
20241×
0.47May 27, 2024
20231×
0.90May 29, 2023
20221×
0.50Jun 1, 2022